Physician profile
John E Jacoby
NPI 1790853778
$2,836.69
in general payments reported to CMS, 2019-2025
20 companies · $33.42 in 2025
The $33.42 reported for 2025 was less than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $966 · 2020: $300 · 2021: $538 · 2022: $860 · 2023: $140 · 2025: $33.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $173.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $599.42 | 2019-2023 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $569.84 | 2019-2023 | Trelegy Ellipta |
| Abbvie INC. | $382.07 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $261.16 | 2019 | |
| Genentech USA, INC. | $169.34 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $155.01 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $137.04 | 2019-2022 | |
| Daiichi Sankyo INC. | $112.02 | 2019 | |
| Lilly USA, LLC | $78.64 | 2019 | |
| Astellas Pharma US INC | $74.99 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.85 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $45.75 | 2021 | |
| Arbor Pharmaceuticals, INC. | $34.45 | 2019 | |
| Incyte Corporation | $33.80 | 2022 | |
| Exact Sciences Corporation | $33.42 | 2025 | Cologuard Collection Kit |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $26.88 | 2023 | |
| Idorsia Pharmaceuticals US INC | $23.54 | 2022 | |
| Janssen Pharmaceuticals, INC | $20.64 | 2021 | |
| Merck Sharp & Dohme LLC | $15.07 | 2019 | |
| Nevro Corp. | $14.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Jacoby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.